Immune-related gigantomastia: a case study

Alessia Lozito1, Maria Gemelli2, Donata Micello3

  • 1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, 20090, Italy.

Immunotherapy
|July 11, 2023
PubMed

PD-1/PDL-1 inhibitors have revolutionized cancer treatment, especially in lung cancer. Despite their efficacy, a new spectrum of side effects, called immune-related adverse events, may occur and their management could be difficult. Gigantomastia, a rare condition characterized by excessive growth of the breasts, has been associated with some drugs, but no correlation with immunotherapy has ever been reported. Here, we report the case of a possible immune-related gigantomastia.